From Nasdaq, Inc.:



– NKGen Biotech Inc. has received clearance from Health Canada for its Clinical Trial Application for a Phase 1/2a study to evaluate the safety, tolerability, and exploratory efficacy of SNK01 natural killer cell therapy for the treatment of patients with moderate Alzheimer’s Disease.
– The U.S. Phase 1/2a trial of SNK01 in moderate Alzheimer’s disease patients officially opened with the first patient enrolled in December 2023.
– The approved trial of approximately 36 patients with moderate AD is expected to commence in December 2023 with the first interim data expected in the third quarter of 2024. Phase 1 is an open label safety evaluation to determine the maximum tolerated dose and/or recommended Phase 2 dose of SNK01, while Phase 2 is a randomized, placebo-controlled, multicenter trial evaluating the safety and efficacy of SNK01 in moderate AD patients.



Read more: NKGen Biotech Receives Clearance For SNK01 NK Cell Therapy Clinical Trial From Health Canada